Kameel Farag Buys Shares of Akari Therapeutics, Plc $AKTX
Key Points
- Kameel Farag bought 18,830 shares of Akari Therapeutics, Plc ($AKTX) worth $105,005.50.
- $AKTX last traded around $9.52.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kameel Farag, Interim CFO at Akari Therapeutics, Plc ($AKTX), bought 18,830 shares at an average price of $5.58, for a total transaction of $105,005.50. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Akari Therapeutics, Plc Stock Down 11.0%
Shares of Akari Therapeutics, Plc ($AKTX) traded around $9.52 on Friday, down 11.0% for the day.
Akari Therapeutics, Plc Earnings
Analysts Set New Price Targets
About Akari Therapeutics, Plc
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Get Akari Therapeutics, Plc alerts
New 13F filings, insider trades, and analyst moves on $AKTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.